AstraZeneca PLC, AZN, AZN.L, ZEG.DE, AZN.ST, FDA Calendar, PDUFA Date

Company Name	AstraZeneca PLC AZN, AZN.L, ZEG.DE, AZN.ST
Drug Name	Camizestrant (NDA)
Event Name	FDA panel to review Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy whose tumours express ESR1 gene mutations
Event Date	04/30/2026
Outcome Date	04/30/2026
Outcome	FDA panel voted against recommending approval of Camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer on Apr.30, 2026
Drug Status
Rival Drugs	ORSERDU, developed by Stemline Therapeutics; Lilly's Inluriyo
Market Potential	Analysts estimate peak sales for Camizestrant to range between $1.5 billion and $3 billion.
Other Approvals
News

Return to FDA Calendar

Slide Shows